ClinicalTrials.gg
CompletedNCT02672852Updated Oct 9, 2019Results posted

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

A Phase 3 interventional study of Risankizumab and Placebo in Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
5th of 30
507 · median 162
Started
2016
with 5 others
Phase 3
17 of 30
none open now
Registered
4th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 5th largest by enrollment, is one of 6 that started in 2016, is one of 17 in phase 3, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque psoriasis.

Read the detailed description

In Part A1, eligible participants were randomized at Baseline at a ratio of 4:1, stratified by weight and prior exposure to tumor necrosis factor antagonists to receive double-blind (DB) risankizumab 150 mg or placebo at Weeks 0 and 4. In Part A2, participants randomized at Baseline to receive DB placebo then received risankizumab 150 mg at Weeks 16 (Part A2) and at Week 28 and every 12 weeks up to 88 weeks (Part B); participants randomized to risankizumab 150 mg continued to receive risankizumab 150 mg at Week 16. Participants who received risankizumab in Part A and were nonresponders (sPGA >2) at Week 28 received risankizumab 150 mg at Week 28 and every 12 weeks up to 88 weeks (Part B). In Part B, participants who received risankizumab in Part A and were responders (sPGA ≤2) at Week 28, were rerandomized at a ratio of 1:2 to receive DB risankizumab 150 mg or placebo at Week 28 and every 12 weeks up to 88 weeks (Part B). Starting at Week 32, rerandomized participants who reached relapse (defined as sPGA ≥3) were switched to risankizumab 150 mg every 12 weeks.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
  • risankizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants. Woman of must be ready and willing to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1 percent per year when used consistently and correctly.
  • Age ≥18 years at screening
  • Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the participant.
  • Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomization); Have an involved body surface area (BSA) ≥ 10% and Have a Psoriasis Area and Severity Index (PASI) ≥ 12 and Have a static Physician Global Assessment (sPGA) score of ≥ 3.
  • Must be a candidate for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator
  • Signed and dated written prior to admission to the study and performance of any study procedures in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  • Participants with nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular); current drug-induced psoriasis (including a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium); active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to the investigators judgment.
  • Previous exposure to ABBV-066
  • Currently enrolled in another study or less than 30 days (from screening) since completing another investigational study
  • Use of any restricted medication as noted or any drug considered likely to interfere with the safe conduct of the study.
  • Major surgery performed within 12 weeks prior to randomization or planned within 12 months after screening (e.g., hip replacement, removal aneurysm, stomach ligation).
  • Known chronic or relevant acute infections such as active tuberculosis, (HIV), or viral hepatitis
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix
  • Evidence of a current or previous disease (including chronic alcohol or drug abuse), medical condition other than psoriasis, surgical procedure (i.e., organ transplant), medical examination finding (including vital signs and [ECG]), or laboratory value at the screening visit outside the reference range that in the opinion of the Investigator, is and would make the study participant unable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data.
  • History of allergy/ to a systemically administered biologic agent or its
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Previous enrolment in this trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).

    Drug: Risankizumab

  • Placebo comparator
    Placebo

    Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).

    Drug: Placebo

Interventions

  • Risankizumab administered by subcutaneous injection

    Also known as: BI 655066, ABBV-066, SKYRIZI

  • DrugPlacebo

    Placebo for risankizumab administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Non-responder imputation (NRI) was used for missing data.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 16

  3. Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 16

  2. Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 16

  3. Percentage of Participants Achieving an sPGA Score of Clear at Week 16

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 16

  4. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16

    The DLQI is a 10-question questionnaire that asks the participant to evaluate the degree that psoriasis has affected their quality of life in the last week and includes 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment). Responses to each domain are not relevant (0), not at all (0), a little (1), a lot (2), and very much (3). The DLQI is calculated by summing the scores of the questions and ranges from 1 to 30, where 0-1 = no effect on patient's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on patient's life. The higher the score, the more the quality of life is impaired. NRI was used for missing data.

    Time frame: Week 16

  5. Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 104

  6. Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 52

  7. Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 52

  8. Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 52

07

Results

Posted May 28, 2019

Participant flow

Part A1
Participant flow — Part A1
MilestonePlacebo (Part A1)Risankizumab (Part A1)Placebo/Risankizumab Part A2/Part BRisankizumab/Risankizumab Part A2Risankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)Risankizumab/Risankizumab Part B (Nonresponders)
Started10040700000
Completed9740300000
Not completed3400000
Withdrew: Disease worsening1000000
Withdrew: Adverse event0100000
Withdrew: Lost to follow-up1200000
Withdrew: Withdrawal by subject1100000
Part A2
Participant flow — Part A2
MilestonePlacebo (Part A1)Risankizumab (Part A1)Placebo/Risankizumab Part A2/Part BRisankizumab/Risankizumab Part A2Risankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)Risankizumab/Risankizumab Part B (Nonresponders)
Started0093403000
Completed0083399000
Not completed00104000
Withdrew: Disease worsening0010000
Withdrew: Adverse event0030000
Withdrew: Lost to follow-up0020000
Withdrew: Withdrawal by subject0010000
Withdrew: Other0030000
Withdrew: Not entered in part b0004000
Part B
Participant flow — Part B
MilestonePlacebo (Part A1)Risankizumab (Part A1)Placebo/Risankizumab Part A2/Part BRisankizumab/Risankizumab Part A2Risankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)Risankizumab/Risankizumab Part B (Nonresponders)
Started000022511163
Completed000020910051
Not completed0000161112
Withdrew: Disease worsening0000101
Withdrew: Worsening pre-existing condition0000010
Withdrew: Other adverse event0000351
Withdrew: Lost to follow-up0000341
Withdrew: Withdrawal by subject0000507
Withdrew: Other0000412

Outcome measures

PrimaryPercentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Non-responder imputation (NRI) was used for missing data.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16
percentage of participantsPlacebo (Part A1)Risankizumab (Part A1)
Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 162.073.2
Statistical analysis
  • Placebo (Part A1) vs Risankizumab (Part A1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 70.8 · 95% CI 65.7 to 76.0
PrimaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16
percentage of participantsPlacebo (Part A1)Risankizumab (Part A1)
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 167.083.5
Statistical analysis
  • Placebo (Part A1) vs Risankizumab (Part A1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 76.5 · 95% CI 70.4 to 82.5
PrimaryPercentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52
percentage of participantsRisankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)
Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 5261.387.4
Statistical analysis
  • Risankizumab/Placebo (Part B; Rerandomized Responders) vs Risankizumab/Risankizumab (Part B; Rerandomized Responders) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 25.9 · 95% CI 17.3 to 34.6
SecondaryPercentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16
percentage of participantsPlacebo (Part A1)Risankizumab (Part A1)
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 168.088.7
Statistical analysis
  • Placebo (Part A1) vs Risankizumab (Part A1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 80.6 · 95% CI 74.5 to 86.6
SecondaryPercentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16
percentage of participantsPlacebo (Part A1)Risankizumab (Part A1)
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 161.047.2
Statistical analysis
  • Placebo (Part A1) vs Risankizumab (Part A1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 45.5 · 95% CI 40.3 to 50.8
SecondaryPercentage of Participants Achieving an sPGA Score of Clear at Week 16

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an sPGA Score of Clear at Week 16
percentage of participantsPlacebo (Part A1)Risankizumab (Part A1)
Percentage of Participants Achieving an sPGA Score of Clear at Week 161.046.4
Statistical analysis
  • Placebo (Part A1) vs Risankizumab (Part A1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 44.8 · 95% CI 39.5 to 50.0
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16

The DLQI is a 10-question questionnaire that asks the participant to evaluate the degree that psoriasis has affected their quality of life in the last week and includes 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment). Responses to each domain are not relevant (0), not at all (0), a little (1), a lot (2), and very much (3). The DLQI is calculated by summing the scores of the questions and ranges from 1 to 30, where 0-1 = no effect on patient's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on patient's life. The higher the score, the more the quality of life is impaired. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16
percentage of participantsPlacebo (Part A1)Risankizumab (Part A1)
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 163.065.4
Statistical analysis
  • Placebo (Part A1) vs Risankizumab (Part A1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 62.1 · 95% CI 56.4 to 67.9
SecondaryPercentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104
percentage of participantsRisankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)
Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 1047.181.1
Statistical analysis
  • Risankizumab/Placebo (Part B; Rerandomized Responders) vs Risankizumab/Risankizumab (Part B; Rerandomized Responders) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 73.9 · 95% CI 66.0 to 81.9
SecondaryPercentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52
percentage of participantsRisankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 5271.692.8
Statistical analysis
  • Risankizumab/Placebo (Part B; Rerandomized Responders) vs Risankizumab/Risankizumab (Part B; Rerandomized Responders) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 21.2 · 95% CI 13.7 to 28.7
SecondaryPercentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52
percentage of participantsRisankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)
Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 5252.485.6
Statistical analysis
  • Risankizumab/Placebo (Part B; Rerandomized Responders) vs Risankizumab/Risankizumab (Part B; Rerandomized Responders) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 33.1 · 95% CI 24.0 to 42.2
SecondaryPercentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52
percentage of participantsRisankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 5230.264.0
Statistical analysis
  • Risankizumab/Placebo (Part B; Rerandomized Responders) vs Risankizumab/Risankizumab (Part B; Rerandomized Responders) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted percentage difference: 33.7 · 95% CI 23.2 to 44.2

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug (up to 103 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Part A1)0/100 (0%)8/100 (8%)17/100 (17%)
Risankizumab (Part A1)0/407 (0%)8/407 (2%)52/407 (12.8%)
Risankizumab/Placebo (Part B; Rerandomized Responders)0/225 (0%)17/225 (7.6%)92/225 (40.9%)
Risankizumab/Risankizumab (Part B; Rerandomized Responders)2/111 (1.8%)13/111 (11.7%)52/111 (46.8%)
Any Risankizumab4/500 (0.8%)55/500 (11%)242/500 (48.4%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventPlacebo (Part A1)Risankizumab (Part A1)Risankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)Any Risankizumab
Alcoholic pancreatitisGastrointestinal disorders1/1000/4070/2250/1110/500
Inguinal herniaGastrointestinal disorders1/1000/4070/2250/1110/500
Liver injuryHepatobiliary disorders1/1000/4070/2250/1110/500
CellulitisInfections and infestations1/1000/4070/2250/1112/500
Cerebrovascular accidentNervous system disorders1/1000/4071/2250/1110/500
Transient ischaemic attackNervous system disorders1/1000/4070/2250/1110/500
AlcoholismPsychiatric disorders1/1000/4070/2250/1110/500
AnxietyPsychiatric disorders1/1000/4070/2250/1110/500
InsomniaPsychiatric disorders1/1000/4070/2250/1110/500
Suicidal ideationPsychiatric disorders1/1000/4071/2250/1110/500
Most frequent other events
Most frequent other events
EventPlacebo (Part A1)Risankizumab (Part A1)Risankizumab/Placebo (Part B; Rerandomized Responders)Risankizumab/Risankizumab (Part B; Rerandomized Responders)Any Risankizumab
NasopharyngitisInfections and infestations6/10021/40745/22523/111116/500
Upper respiratory tract infectionInfections and infestations5/1006/40723/22516/11177/500
ArthralgiaMusculoskeletal and connective tissue disorders2/1007/40713/22510/11135/500
HeadacheNervous system disorders0/10014/4077/2258/11134/500
InfluenzaInfections and infestations1/1003/4078/2257/11122/500
Back painMusculoskeletal and connective tissue disorders0/1002/40712/2254/11128/500
PsoriasisSkin and subcutaneous tissue disorders5/1002/4078/2250/1114/500

Baseline characteristics

Intent to Treat (ITT) Population in Part A1 (ITT_A1): All participants who were randomized at Baseline

Age, Continuous
Age, Continuous(years)Placebo (Part A1)Risankizumab (Part A1)Total
Mean47.9 ± 13.7849.6 ± 13.1749.2 ± 13.30
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Part A1)Risankizumab (Part A1)Total
Female27124151
Male73283356
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (Part A1)Risankizumab (Part A1)Total
Hispanic or Latino114556
Not Hispanic or Latino89362451
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Part A1)Risankizumab (Part A1)Total
American Indian or Alaska Native000
Asian156479
Native Hawaiian or Other Pacific Islander134
Black or African American21820
White82320402
More than one race022
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lebwohl MG, Soliman AM, Yang H, Wang J, Hagan K, Padilla B, Pinter A. Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials. Dermatol Ther (Heidelb). 2022 Feb;12(2):407-418. doi: 10.1007/s13555-021-00660-3. Epub 2021 Dec 18. PubMed 34921669 ↗
  • Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723. PubMed 32267471 ↗
  • Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clin Pharmacokinet. 2020 May;59(5):575-589. doi: 10.1007/s40262-019-00829-2. PubMed 31667790 ↗
  • Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019 Oct;58(10):1309-1321. doi: 10.1007/s40262-019-00759-z. PubMed 31054118 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Aug 2017, 17 months.

Results were first posted in May 2019, 1 year 9 months after primary completion. A results delay was requested in Oct 2017.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2016
First posted
Feb 3, 2016
StartActual
Feb 29, 2016
Primary completionActual
Aug 2, 2017
CompletionActual
Jul 26, 2018
Results delay requested
Oct 31, 2017
Results first posted
May 28, 2019
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02672852
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 3, 2016
Start date
Feb 29, 2016
Primary completion
Aug 2, 2017
Completion
Jul 26, 2018
Results posted
May 28, 2019
Last update
Oct 9, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion